Pancreatic ductal adenocarcinoma (PDA) has a very poor prognosis and is a highly lethal malignancy. At present,the main method of clinical treatment of PDA is surgical resection,other treatment methods are mainly chemotherapy,or chemotherapy combined with radiotherapy. Many clinical trials try to use immune methods to treat PDA,including the use of immune checkpoint inhibitors,PDA vaccine,adoptive T cell therapy,etc.,and try to combine drugs on the basis of immunotherapy,when immunotherapy is combined with other ways,there can be a synergistic effect to enhance the effect of drug action. In this review,we discuss the status,resistance mechanism,achievements and development direction of immunotherapy in PDA.
维普
万方数据